GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

Phase 3

Active, not recruiting

Conditions: HIV-1-Infection

Interventions: Drug: ISL/LEN
Drug: Antiretroviral Combinations

First Posted Date: 2024-10-08

Last Posted Date: 2025-05-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 600

Registration Number: NCT06630299

Locations: 🇺🇸
University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
🇺🇸
University of Alabama at Birmingham(UAB) 1917 Research Clinic, Birmingham, Alabama, United States
🇺🇸
Pueblo Family Physicians, Phoenix, Arizona, United States

and more 94 locations

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

Phase 2

Recruiting

Conditions: HIV-1-infection

Interventions: Drug: GS-1720
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Drug: GS-1720/GS-4182 FDC
Drug: GS-4182
Drug: Placebo to Match BVY
Drug: Placebo to Match GS1720/GS-4182 FDC

First Posted Date: 2024-09-26

Last Posted Date: 2025-05-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 675

Registration Number: NCT06613685

Locations: 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸
Hospital Universitario Virgen de la Victoria, Malaga, Spain
🇵🇷
Proyecto ACTU, San Juan, Puerto Rico

and more 49 locations

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Phase 2

Recruiting

Conditions: RSV Infection

Interventions: Drug: Obeldesivir
Drug: Obeldesivir Placebo

First Posted Date: 2024-09-05

Last Posted Date: 2025-03-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 240

Registration Number: NCT06585150

Locations: 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸
Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸
Lakeview Clinical Research, LLC, Guntersville, Alabama, United States

and more 114 locations

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Recruiting

Conditions: Weight Management

Interventions: Drug: GS-4571
Drug: Placebo
Drug: Omeprazole

First Posted Date: 2024-08-20

Last Posted Date: 2025-04-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 134

Registration Number: NCT06562907

Locations: 🇺🇸
ICON, Salt Lake City, Utah, United States
🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States

Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

Phase 2

Active, not recruiting

Conditions: HIV-1-Infection

Interventions: Drug: GS-1720/GS-4182 FDC
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Drug: Placebo to Match BVY
Drug: GS-1720
Drug: Placebo to Match GS1720/GS-4182 FDC
Drug: GS-4182

First Posted Date: 2024-08-09

Last Posted Date: 2024-12-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 675

Registration Number: NCT06544733

Locations: 🇺🇸
UAB 1917 Research Clinic, Birmingham, Alabama, United States
🇺🇸
Pacific Oaks Medical Group, Beverly Hills, California, United States
🇺🇸
Be Well Medical Center, Berkley, Michigan, United States

and more 34 locations

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Phase 2

Recruiting

Conditions: HIV-1-infection

Interventions: Drug: Lenacapavir
Drug: BIC/LEN FDC

First Posted Date: 2024-08-01

Last Posted Date: 2025-03-25

Lead Sponsor: Gilead Sciences

Target Recruit Count: 75

Registration Number: NCT06532656

Locations: 🇺🇸
Children's National Hospital, Washington, District of Columbia, United States
🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Grady Ponce de Leon Center, Atlanta, Georgia, United States

and more 14 locations

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: GS-2121
Drug: Zimberelimab

First Posted Date: 2024-08-01

Last Posted Date: 2025-05-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 154

Registration Number: NCT06532565

Locations: 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States

and more 3 locations

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

Phase 2

Recruiting

Conditions: Pre-Exposure Prophylaxis of HIV Infection

Interventions: Drug: Lenacapavir Injection
Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Drug: Lenacapavir Tablet

First Posted Date: 2024-07-22

Last Posted Date: 2025-02-13

Lead Sponsor: Gilead Sciences

Target Recruit Count: 262

Registration Number: NCT06513312

Locations: 🇫🇷
Hopital Avicenne, Bobigny, France
🇫🇷
Hopital Europeen Marseille, Marseille, France
🇫🇷
CHU Nice Archet, Nice, France

and more 11 locations

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy

Phase 3

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Doxorubicin
Drug: Sacituzumab govitecan-hziy
Drug: Paclitaxel

First Posted Date: 2024-07-03

Last Posted Date: 2025-05-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 520

Registration Number: NCT06486441

Locations: 🇯🇵
The Cancer Institute Hospital Of JFCR, Tokyo, Japan
🇬🇷
St. Luke's Hospital, Thessaloniki, Greece
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, China

and more 150 locations

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

Phase 4

Recruiting

Conditions: HIV-1-infection

Interventions: Drug: E/C/F/TAF
Drug: F/TAF (High Dose Tablet)
Drug: B/F/TAF (Low Dose)
Drug: E/C/F/TAF (Low Dose)
Drug: F/TAF (Low Dose Tablet)
Drug: F/TAF (Lowest Dose Tablet)
Drug: F/TAF (High Dose TOS)
Drug: B/F/TAF (High Dose)
Drug: F/TAF (Low Dose TOS)
Drug: B/F/TAF (Lowest Dose TOS)
Drug: F/TAF (Lowest Dose TOS)
Drug: B/F/TAF (High Dose TOS)
Drug: Cobicistat (High Dose)
Drug: 3rd ARV Agent
Drug: Cobicistat (Low Dose)
Drug: Cobicistat (TOS)
Drug: B/F/TAF (Low Dose TOS)
Drug: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
Drug: ATV
Drug: DRV
Drug: Lopinavir Boosted with ritonavir (LPV/r)

First Posted Date: 2024-03-29

Last Posted Date: 2025-05-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 350

Registration Number: NCT06337032

Locations: 🇿🇼
University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe
🇦🇷
Helios Salud, Buenos Aires, Argentina
🇿🇦
Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa

and more 9 locations

Home Terms & Conditions Privacy Policy